Psyence BioMed launches psilocybin longevity research program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Psyence BioMed Announces Groundbreaking Psilocybin Longevity Research Program
November 25, 2025 7:00 AM ESTFirst publicly listed company to actively investigate psilocybins potential impact on longevity
NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (Psyence BioMed or the Company), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced the launch of a new psilocybin longevity research initiative in collaboration with leading researchers in South Africa. This program positions Psyence BioMed as the first and currently the only publicly listed company to investigate psilocybins potential impact on biological markers associated with aging and longevity.... More
